Advances and Challenges in Intranasal Biologics
10.13748/j.cnki.issn1007-7693.20231878
- VernacularTitle:鼻用生物制品的进展与挑战
- Author:
MA Linsha
1
,
2
;
JIA Guoshu
3
;
ZHOU Yimeng
4
;
CAO Meng
4
;
LIU Fen
4
Author Information
1. University of Chinese Academy of Sciences, Beijing 100049, China
2. ShanghaiTech University, Shanghai 201210, China
3. China Pharmaceutical University, Nanjing 211198, China
4. Shanghai Center for Drug Evaluation and Inspection, Shanghai 201210, China
- Publication Type:Journal Article
- Keywords:
intranasal biopharmaceutical;
macromolecular drugs;
vaccine;
cell therapy
- From:
Chinese Journal of Modern Applied Pharmacy
2023;40(20):2802-2810
- CountryChina
- Language:Chinese
-
Abstract:
Biologics are developing rapidly and have demonstrated their unique advantages in the treatment of many diseases. And with common administration, like oral and injection, biological products often have problems in instability, short half-life and poor utilization of the central nervous system, which limits the application scope and development of biological products. Intranasal biologics are promising strategy taking advantages in nasal administration that bypass the restrictions in vivo, like blood-brain-barrier, to improve the drug avalibility in the target site, which have potential to improve efficient delivery and the availability. According to published literature, clinical databases, industry guidelines around the world, this review highlighted the rescent progress in intranasal macromolecular drugs, intranasal vaccine and intranasal cell therapy, which were the main fields of intranasal biologics, offering perspectives suggestions for the further development of this field.
